BETA DRUGS LIMITED

Beta Drugs Limited (BETA) presented an overview of its operations and financial performance in its investor presentation dated July 2026. Established in 2005, the company focuses on specialty pharmaceuticals, particularly in oncology, and has expanded into IVF and dermatology. BETA reported a 5-year revenue CAGR of 27% and a 5-year PAT CAGR of 29%. The company operates three WHO-GMP certified manufacturing facilities and serves over 85% of corporate and government hospitals in India, with exports to more than 25 countries. In Q1-FY27, BETA achieved a revenue of INR 1,255 million, reflecting a 25.2% year-on-year growth. The branded oncology segment grew by 47% year-on-year, while the contract manufacturing business increased by 41%. Management highlighted a robust pipeline of new products and a strategic vision for 2030 aimed at enhancing revenue from branded products.

The presentation emphasized strong growth metrics and strategic expansion initiatives.